Sun Pharma Q1: Strong India Growth, Specialty Sales Dip

Sun Pharmaceutical Industries Ltd. presented a complex Q1 earnings report, showcasing stronger-than-expected operating profit and margins even as revenue and net profit fell short of analyst estimates.

Key Q1 Financials

• Consolidated Revenue: Rs. 15,300 crore, up 10.5% year-on-year.
• EBITDA: Rs. 4,419 crore, a 2.7% increase.
• EBITDA Margin: 28.9%, exceeding estimates despite a prior-year decline.
• Net Profit: Rs. 2,895 crore, up 27%, but below expectations.
• One-time Loss: Rs. 204 crore, impacting reported profit.

While the company’s consolidated revenue of Rs. 15,300 crore missed the Bloomberg estimate of Rs. 15,527 crore, its EBITDA of Rs. 4,419 crore surpassed the Rs. 4,372 crore projection. The reported net profit of Rs. 2,895 crore, though up 27%, was below the Rs. 2,974 crore estimate, partly due to a one-time loss of Rs. 204 crore.

India Business Holds Firm

Despite the mixed overall performance, brokerages largely maintained a positive outlook on Sun Pharma’s domestic operations. Macquarie upheld an ‘Outperform’ rating with a target price of Rs. 2,150, citing a robust India business and a favorable product mix.

• Goldman Sachs highlighted that India’s growth stemmed primarily from increased volumes and five new product launches during the quarter.
• HSBC also reiterated a ‘Buy’ rating, adjusting its target price to Rs. 2,120, reflecting consistency within Sun Pharma’s India business.

Specialty Sales and US Market Slowdown

Conversely, BofA reiterated an ‘Underperform’ rating, despite raising its target price to Rs. 1,915 from Rs. 1,720. The brokerage pointed to a 7% sequential decline in US sales and moderating specialty revenue as key areas of concern.

BofA also noted softer growth in emerging markets and a perceived lack of near-term catalysts, painting a more cautious picture for the company’s international specialty segments. HSBC also acknowledged a slowdown in innovative medicine sales growth.

Forward Outlook and Strategic Moves

Management reaffirmed its FY27 guidance, anticipating high-single-digit consolidated revenue growth. Research and development spending is projected to remain between 6-7% of sales over the same period.

The proposed Organon transaction, slated for closure in Q4 FY27 or early CY27, remains a pivotal factor that could significantly influence future earnings and strategic direction for Sun Pharmaceutical Industries.